EVALUASI PENGOBATAN BRONKODILATOR DAN KORTIKOSTEROID PADA PASIEN PPOK DI INSTALASI RAWAT INAP B RSUP FATMAWATI JAKARTA PERIODE JANUARI 2012 - JUNI 2013

Sudrajat Sugiharta

Abstract


ABSTRAK

Penelitian ini dilakukan untuk mengevaluasi pengobatan bronkodilator denganatautanpa kortikosteroid terhadap perubahan kadar PCO2dan PO2 arterial pasien PPOK di rawat inap B RSUP Fatmawati. Desain penelitian ini yaitu penelitian observasional analitik dengan pengambilan data dilakukan secara retrospektif dari rekam medik pasien dari tanggal 1 Januari 2012 hingga 29 Juni 2013.Data pasien yang diambil tercatat 113 pasien PPOK yang memenuhi kriteria inklusiuntukanalisisdeskriptifsedangkansejumlah47 pasien PPOK untuk analisis statistik.Terdapat perbedaan perubahan kadar PCO2 pada pasien yang hanya diberikan bronkodilator sebesar 13,41 mmHg (18,186), sedangkan pada pasien PPOK yang diberikan bronkodilator dan kortikosteroid menunjukan perbedaan perubahan PCO2 sebesar 9,778 mmHg (9,427), Perbedaan perubahan kadar PO2 pada pemberian bronkodilator sebesar 30,485 mmHg (26,07), perbedaan perubahan ini nampak lebih kecil dibandingkan pada pasien yang diberikan bronkodilator dan kortikosteroid dengan kadar PO2 sebesar 44,011 mmHg (29,112) namun secara statistik perbedaan kadar ini tidak menunjukan perbedaan yang bermakna. Penelitian menyimpulkan bahwa terdapat perbedaan perubahan kadar PCO2 dan PO2yang tidak bermakna pada pasien yang mendapatkan pengobatan bronkodilator tanpa kortikosteroid dengan pasien yang mendapatkan pengobatan bronkodilator dengan kortikosteroid.

Kata kunci: PPOK, Eksaserbasi akut, RSUP Fatmawati, PCO2, PO2, Kortikosteroid

ABSTRACT

This study was conducted to evaluate the bronchodilator with or without  corticosteroid treatment againts changes in levels of arterial PCO2 and PO2 in COPD patients that hospitalized in Fatmawati hospital.This study design is observational analytic study with retrospective data collection from medical records of patients from January 1, 2012 to June 29, 2013. Recorded patient data captured 113 COPD patients who met the inclusion criteria for the descriptive analysis, while a number of 47 patients with COPD for statistical analysis. There are difference changes in PCO2 levels in patients who given bronchodilators 13.41 mmHg (18.186), whereas in COPD patients were given bronchodilators and corticosteroids showed a difference changePCO2of 9.778 mmHg  (9.427), difference changes in levels of PO2 in treatment of a bronchodilator was 30.485 mmHg (26.07), this difference change seems smaller than in patients given bronchodilators and corticosteroids with PO2 levels of 44.011 mmHg (29.112) but in statistically showed no significant difference. The study concluded that there were no significant differences levels of PCO2 and PO2 changesin patients receiving bronchodilator treatment alone with patients receiving bronchodilator treatment with corticosteroids.

Key word: COPD, acute exacerbations, Fatmawati hospital, PCO2, PO2, Corticosteroid


Full Text:

PDF

References


COPD International [Internet]. Nashua: COPD International. Diambil dari: www.copd-international.com./COPD.htm Diakses 12 september 2012.

Rodriguez-Roisin R, Anzueto A, Bourbeau J, deGuia TS, Hui DSC, Jenkins C, et al. Global initiative for chronic obstructive lung disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, Update 2010. Spain: GOLD, Inc; 2010.

Akinbami LJ, liu X. Chronic Obstructive Pulmonary Disease Among Adults Aged 18 and Over in the United States, 1998–2009 [Internet]. Hyattsville: Centers for Disease Control and Prevention; 2011. Diambil dari: http://www.cdc.gov/nchs/data/databriefs/db63.htm. Diakses 7 Oktober 2012

Guidelines for the Diagnosis and Treatment of COPD (Chronic Obstructive Pulmonary Disease). 3rd ed. Japan: The Japanese Respiratory Society; 2010, h 1-31.

Depkes RI. Pedoman Pengendalian Penyakit Paru Obstruktif Kronik (PPOK). Depkes RI, Dirjen PPL. 2008

Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: role of comorbidities. Eur Respir J [Internet]. 2006; 28: h1245-57. Diambil dari: http://www.ersj.org.uk/content/28/6/1245.full. Diakses 14 Oktober 2012.

Stavem K, Aaser E, Sandvik L, Bjørnholt JV, Erikssen, Thaulow E, et al. Lung function, smoking and mortality in a 26-year follow-up of healthy middle-aged males. Eur Respir J 2005; 25: h 618-25. Diambil dari: http://www.ersj.org.uk/content/25/4/618.full?sid=89c54cad-ba75-4773-873a-d423df7571c3. Diakses 1 Agustus 2012.

Celli BR, Macnee W, Agusti A, Anzueto A, Berg B, Buist AS, et al. Standards for the diagnosis and Treatment of Patients with COPD: a Summary of the ATS/ERS position paper. Eur Respir J 2004; 23: h 932-46.

Sukandar EY, Andrajati R, Sigit JI, Adnyana IK, Setiadi AAP, Kusnandar. ISO FARMAKOTERAPI. Jakarta: ISFI Penerbitan, 2008.

Make B, Dutro MP, Paulose-Ram R, Marton JP, Mapel DW. Undertreatment of COPD: a retrospective analysis of US managed care and Medicare patients. Int J Chron Obstruct Pulmon Dis [Internet]. 2012; 7: h 1-9. Diambil dari: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3273365/?tool=pmcentrez. Diakses 9 Oktober 2012.

Sin DD, Paul Man SF. Why Are Patients With Chronic Obstructive Pulmonary Disease at Increased Risk of Cardiovaskular Disease?: The Potential Role of Systemic Inflammation in Chronic Obstructive Pulmonary Disease. Circulation 2003; 107: h 1514-19. Diakses 10 Agustus 2012.

Macchia A, Monte S, Romero M, D’ Ettorre A, Tognoni G, The prognostic influence of chronic obstructive pulmonary disease in patients hospitalized for chronic heart failure. Eur J Heart Fail 2007; 9: h 942-48.

De Lucas-Ramos P, Izquirdo-Alonso JL, Moro JMRG, Bellón-Cano JM, Ancochea-Bermúdez, Calle-Rubio M, et al. Cardiovascular Risk Factors in Chronic Obstructive

Curkendall SM, De Luise C, Jones JK, Stang MR, Goehring Jr E, et al. Cardiovaskular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada Cardiovascular Disease in COPD Patients. Ann Epidemiol 2006; 16: h 63-70.

Falk JA, Kadiev S, Criner GJ, Scharf SM, Minai OA, Diaz P. Cardiac Disease in Chronic Obstructive Pulmonary Disease. Proc Am Thorac Soc 2008; 5: h 543-8.

Bellami D. COPD exacerbations – diagnosis, management and prevention. Practice Nurse 2006;13, 6:35-42. Diambil dari: http://www.who.int/respiratory/copd/burden/en/index.html. Diakses 25 September 2012. Diakses 25 September 2012.

Macnee W. Chronic Bronchitis and Emphysema. In : Seaton A, Seaton D, Leitch AG, editors. Crofton and Douglas’s Respiratory Diseases. Vol 1. 5th ed. London. Blackwell Science;2000. h 617-695.

Penyakit Paru Obstruktif Kronik (PPOK), Pedoman Diagnosis & Penatalaksanaan di Indonesia. Jakarta: Perhimpunan Dokter Paru Indonesia; 2003.

Silverman EK, Weiss ST, Drazen JM, Chapman HA, Carey V, Campbell EJ, et al. Gender-related differences in severe early onset chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;162(6): h 2152-2158.

Baxter K. Stockley’s drug interactions, eighth edition. London: Pharmaceutical Press; 2008

Cosio BG, Agusti A. Update in Chronic Obstrucitve Pulmonary Disease Pulmonary and Critical Care Update. 2009: h 656-57.

KEPMENKES RI. NO. 1022/MENKES/SK/XI/2008TentangPedoman Pengendalian Penyakit Paru Obstruktif KronikMenteri Kesehatan Republik Indonesia. Jakarta: Kementerian Kesehatan RI; 2008.

Rahman I. Antioxidant therapies in COPD.Int J Chron Obstruct Pulmon Dis. 2006: 1(1); 15-29.

Casaburi R, Mahler DA, Jones PW, Wanner A, San Pedro G, ZuWallack RL, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19: h 217-24.

Oktorina Y, Jemadi, Rasmaliah. Karakteristik Penderita Penyakit Paru Obstruktif Kronik yang dirawat inap di Rumah Sakit Martha Friska Medan tahun 2010-2011. Fakultas Kesehatan Masyarakat Universitas Sumatera Utara. 2011

Yang L, Zhou M,Smith M, Yang G, Peto R,Wang J.Body mass index and chronic obstructivepulmonary disease-related mortality: anationally representative prospectivestudy of 220 000 men in China. International Journal of Epidemiology 2010;39: h 1027–36

Lacy CF, Armstron LL, Goldman MO, Lance LL. Drug Information Handbook, 17th Edition. Newyork: Lexicomp; 2007.

Tatro DS. Drug Interaction Facts, Oktober 2012. St. Louis Missouri: A Wolter Kluwer Company. 2012

Khoukaz G, Gross NJ. Effects of Salmeterol on Arterial Blood Gases in Patients with Stable Chronic Obstructive Pulmonary Disease, Comparison with Albuterol and Ipratropium. Am J Respir Crit Care Med 1999: 160; h 1028-30

Ozdemir T, Geçkin E, Oğüş Cs Cilli A.Effects of salbutamol and ipratropium bromide on arterial blood gases in patients with stable COPD. Tuberk Toraks. 2003:51(2); h 132-7

Rodrı´guez-Roisin R. COPD exacerbation. 5: Management, Review Series.Thorax 2006: 6; h 535–44

Sacher RA, McPherson RA. Tinjauan Klinis Hasil Pemeriksaan Laboratorium, edisi 11. Jakarta: EGC; 2004.




DOI: https://doi.org/10.52447/scpij.v1i1.309

Refbacks

  • There are currently no refbacks.